1: Amer AM, Allam AN, Abdallah OY. Comparative Pharmaceutical Evaluation of
Candesartan and Candesartan Cilexetil: Physicochemical Properties, In Vitro
Dissolution and Ex Vivo In Vivo Studies. AAPS PharmSciTech. 2017 Sep 25. doi:
10.1208/s12249-017-0879-x. [Epub ahead of print] PubMed PMID: 28948575.
<br>
2: AboulFotouh K, Allam AA, El-Badry M, El-Sayed AM. Development and in vitro/in
vivo performance of self-nanoemulsifying drug delivery systems loaded with
candesartan cilexetil. Eur J Pharm Sci. 2017 Nov 15;109:503-513. doi:
10.1016/j.ejps.2017.09.001. Epub 2017 Sep 6. PubMed PMID: 28889028.
<br>
3: Sunami E, Nomura K, Nishiyama Y, Katayama Y. Effects of Candesartan Cilexetil
Compared with Amlodipine on Serum Asymmetric Dimethylarginine Levels in the
Chronic Stage of Cerebral Infarction: A Preliminary Study. J Nippon Med Sch.
2016;83(6):272-276. doi: 10.1272/jnms.83.272. PubMed PMID: 28133009.
<br>
4: Dudhipala N, Veerabrahma K. Candesartan cilexetil loaded nanodelivery systems
for improved oral bioavailability. Ther Deliv. 2017 Feb;8(2):79-88. doi:
10.4155/tde-2016-0063. PubMed PMID: 28088883.
<br>
5: Park DB, Jang K, Lee JW, Park CW, Lee BH, Kim MG, Jeon JY. Pharmacokinetic and
bioequivalence study comparing a candesartan cilexetil/rosuvastatin calcium
fixed-dose combination with the concomitant administration of candesartan
cilexetil and rosuvastatin calcium in healthy Korean subjects
. Int J Clin
Pharmacol Ther. 2017 Mar;55(3):286-294. doi: 10.5414/CP202740. PubMed PMID:
28079517.
<br>
6: Paudel A, Ameeduzzafar, Imam SS, Fazil M, Khan S, Hafeez A, Ahmad FJ, Ali A.
Formulation and Optimization of Candesartan Cilexetil Nano Lipid Carrier: In
Vitro and In Vivo Evaluation. Curr Drug Deliv. 2017;14(7):1005-1015. doi:
10.2174/1567201813666161230141717. PubMed PMID: 28034361.
<br>
7: Kjeldsen SE, Dzongowski P, Li N, Wang L, Radlmaier A. Fixed-dose combination
of nifedipine gastrointestinal therapeutic system and candesartan cilexetil in
patients with moderate-to-severe essential hypertension: an open-label, long-term
safety and efficacy study. J Clin Pharm Ther. 2016 Dec;41(6):695-702. doi:
10.1111/jcpt.12451. Epub 2016 Sep 27. PubMed PMID: 27670639.
<br>
8: Patel R, Palmer JL, Joshi S, Di Ció Gimena A, Esquivel F. Pharmacokinetic and
Bioequivalence Studies of a Newly Developed Branded Generic of Candesartan
Cilexetil Tablets in Healthy Volunteers. Clin Pharmacol Drug Dev. 2017
Sep;6(5):492-498. doi: 10.1002/cpdd.321. Epub 2016 Dec 22. PubMed PMID: 27753282.
<br>
9: Surampalli G, Nanjwade BK, Patil PA, Chilla R. Novel tablet formulation of
amorphous candesartan cilexetil solid dispersions involving P-gp inhibition for
optimal drug delivery: in vitro and in vivo evaluation. Drug Deliv. 2016
Sep;23(7):2124-2138. Epub 2014 Jul 31. PubMed PMID: 25080228.
<br>
10: Ertürk AS, Gürbüz MU, Tülü M. The effect of PAMAM dendrimer concentration,
generation size and surface functional group on the aqueous solubility of
candesartan cilexetil. Pharm Dev Technol. 2017 Feb;22(1):111-121. doi:
10.1080/10837450.2016.1219372. Epub 2016 Sep 8. PubMed PMID: 27484586.
|